Evommune, Inc. (NYSE:EVMN) Stock Has Average Price Target of $33.33

Shares of Evommune, Inc. (NYSE:EVMN) have received a consensus recommendation of “Moderate Buy” from the fifteen ratings firms that are currently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, three have issued a hold rating, ten have assigned a buy rating and one has issued a strong buy rating on the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $33.33.

EVMN has been the topic of a number of research analyst reports. Stifel Nicolaus set a $30.00 price target on shares of Evommune in a report on Wednesday, September 9th. HC Wainwright restated a “neutral” rating on shares of Evommune in a report on Wednesday, September 9th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Evommune in a research report on Friday, September 18th. Raymond James Financial set a $18.00 price target on Evommune in a research report on Wednesday, September 9th. Finally, William Blair downgraded Evommune from an “outperform” rating to a “market perform” rating in a report on Monday, June 29th.

Evommune Stock Down 4.7%

Shares of NYSE:EVMN opened at $6.87 on Friday. The company has a market cap of $249.35 million and a P/E ratio of -0.62. The business has a fifty day simple moving average of $11.67 and a 200-day simple moving average of $17.77. Evommune has a 52 week low of $6.74 and a 52 week high of $33.20.

Evommune (NYSE:EVMN) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.89) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.21). Sell-side analysts expect that Evommune will post -3.29 earnings per share for the current fiscal year.

Insider Transactions at Evommune

In other Evommune news, Director Arthur S. Kirsch acquired 10,000 shares of the firm’s stock in a transaction on Tuesday, July 7th. The stock was bought at an average cost of $13.30 per share, for a total transaction of $133,000.00. Following the completion of the purchase, the director directly owned 10,000 shares in the company, valued at $133,000. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 31.10% of the stock is currently owned by corporate insiders.

Institutional Trading of Evommune

Large investors have recently added to or reduced their stakes in the stock. EQT Fund Management S.a r.l. acquired a new stake in Evommune during the 4th quarter valued at $84,395,000. Nan Fung Group Holdings Ltd purchased a new stake in Evommune during the 4th quarter worth approximately $24,670,000. Janus Henderson Group PLC acquired a new position in shares of Evommune in the 1st quarter valued at approximately $20,615,000. Eventide Asset Management LLC purchased a new position in shares of Evommune during the 4th quarter valued at approximately $16,461,000. Finally, Defilade Capital Management L.P. grew its position in shares of Evommune by 215.0% during the first quarter. Defilade Capital Management L.P. now owns 678,589 shares of the company’s stock worth $15,601,000 after buying an additional 463,171 shares in the last quarter.

Evommune Company Profile

Evommune, Inc is a clinical-stage biotechnology company focused on developing new treatments for immune-mediated inflammatory diseases. The company’s research is centered on identifying therapies that address the underlying biological mechanisms driving chronic inflammation rather than primarily treating symptoms.

Evommune is advancing a pipeline of investigational medicines designed for conditions with significant unmet medical needs, including dermatologic and other inflammatory disorders.